Liquid Biopsy
News and reporting on cell-free DNA testing.
The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has advantages over PET imaging.
Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.
OneCell Diagnostics Raises $16M in Series A Round
The precision oncology company plans to bring its OncoIndx Ikon liquid biopsy circulating tumor cell detection test to the US market.
Breakthrough Genomics Partners With PRECEDE Pancreatic Cancer Consortium
The PRECEDE Consortium will help with the clinical evaluation of Breakthrough's blood-based pancreatic cancer early detection test.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.